Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET[1] ...

A recent US study raises concerns about the increasing use of CT scans in India, potentially leading to a rise in ...

Illuccix, after radiolabelling with gallium-68, is indicated in France for the detection of prostate-specific membrane ...